Supernus completes its merger with Indivior
The combined company is a diversified, scaled biopharmaceutical firm focused on central nervous system diseases, and will continue the Powering Recovery initiative.
See the latest news and media coverage for Supernus. We track all announcements, press releases, and industry mentions in real time, all in one place.
Central nervous system biopharmaceutical company
indivior.comLast updated
In short: Supernus completed its merger with Indivior, creating a CNS-focused company with $125 million in expected annual synergies.
The combined company is a diversified, scaled biopharmaceutical firm focused on central nervous system diseases, and will continue the Powering Recovery initiative.
Net revenue grew 13% to $356 million with adjusted EBITDA up 76% to $211 million as the company prepares for its Supernus merger on November 2.
Approved by 94% of votes on October 15 for a November 2 closing, creating Supernus Inc trading as SUPN. The deal combines CNS-focused biopharmaceutical capabilities into a diversified company.
The $8.13 per share dividend pays after Nov 2 merger with Supernus closes. Indivior won't pay if the deal fails.
Detailed price information for Indivior Pharmaceuticals Inc (INDV-Q) from The Globe and Mail including charting and trades.
Indivior Pharmaceuticals (NasdaqGS: INDV) reported record third quarter results, highlighting its strongest Q3 performance to date. Shareholders approved a merger with Supernus Pharmaceuticals that will...
Indivior plc. (INDV.L) reported a profit for its third quarter that Increases, from last year The company's bottom line totaled $137 million, or $1.12 per...
Supernus merges with Indivior, converting shares into a 43.5% stake in a $2.2B CNS revenue company with 40% margins.
Track Supernus and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.